Novo Nordisk, Eli Lilly lead industrywide sales surge in Q4

In a year that started with more than two-thirds of biopharma companies posting year-over-year revenue declines in the first quarter, it has finished with an about-face for the industry as evidenced by quarterly reports presented over the last few weeks.